Latest Breaking News On - Study group at brigham - Page 1 : comparemela.com

Study Finds Olezarsen Cuts Triglyceride Levels by About Half

Results show drug is effective and safe, leaves open question of optimal dosing

Brian bergmarkBrian bergmanStudy group at brighamIonis pharmaceuticals incAmerican college of cardiology annual scientific sessionHarvard medical schoolAmerican collegeAnnual scientificMyocardial infarctionStudy groupIonis pharmaceuticalsNew england journal

Monthly olezarsen reduced triglyceride levels by 50%

Monthly olezarsen reduced triglyceride levels by 50%
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Daniel sofferBykatie kalvaitisRichard smithBriana bergmarkAmerican college of cardiology scientific sessionHarvard medical schoolStudy group at brighamOlezarsen ionis pharmaceuticalsMyocardial infarctionStudy groupAmerican collegeCardiology scientificIonis pharmaceuticalsNew england journalPerelman school

Many patients with severe aortic stenosis untreated years after diagnosis

Many patients with severe aortic stenosis untreated years after diagnosis
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesByregina schafferRichard smithEugene braunwaldStudy group at brighamJournal of the american college cardiologyStructural heart program at morristown medical centerAtlantic health systemStructural heart programMorristown medical centerAmerican collegeDistinguished hersey professorHarvard medical school

Successful early studies reported for two Lp(a)-lowering therapies

Successful early studies reported for two Lp(a)-lowering therapies
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Noord hollandSouth australiaSanofi regeneronEli lillyMichellel odonoghueStephenj nichollsByerik swainRichard smithNewamsterdam pharmaBoehringer ingelheimMedicines companyMonash universityEuropean society of cardiology congressStudy group at brighamHarvard medical schoolEuropean society

AMGEN PRESENTS NEW PHASE 2 DATA THAT SHOW OLPASIRAN DELIVERS SIGNIFICANT REDUCTION IN LIPOPROTEIN(A) LEVELS

/PRNewswire/ Amgen (NASDAQ:AMGN) today presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of investigational olpasiran (formerly AMG 890).

Puerto ricoUnited statesColl cardiolMichael strapazonJessica akopyanMichellel odonoghueClin lipidolArterioscler thromb vascDavidm reeseAmerican heart association scientific sessionsScience session of the american heart associationTherapeutics incTeneobio incKyowa kirin co ltdDrug administrationBeigene ltd